Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes
Open accessThe DOI matches its Crossref record; 49 of the 50 references it cites were found in a registry or an index; 17 of the 60 sources its claims cite were checked for support.
Abstract
Background/Objectives: Obesity pharmacotherapy vastly improved the treatment of the disease of obesity. However, GLP-1 receptor agonists and GIP/GLP-1 dual agonists may lead to nutritional complications, including severe caloric restriction, micronutrient deficiencies, lean body mass loss, dehydration, and ketosis. We examine these risks and outlines dietitian-led strategies to support improved safety and effectiveness. Methods: This narrative review was conducted in three stages: literature search, screening of abstracts and full texts, and synthesis of findings. Searches were carried out in April and May 2025 across PubMed, Embase, Scopus, ScienceDirect, Web of Science, and Google Scholar using keywords related to obesity pharmacotherapy and nutrition. Results: Clinical observations and trial data suggest that some individuals may consume fewer than 800 kcal/day during the initial stages of treatment. Prolonged energy and protein deficits can increase the risk of sarcopenia, metabolic dysfunction, and reduce treatment adherence. Additional risks include inadequate micronutrient intake due to reduced dietary variety, dehydration linked to gastrointestinal symptoms and hypodipsia, and rare but serious cases of ketoacidosis. Patients at heightened risk include older adults, those with low baseline muscle mass, and individuals with restrictive eating patterns. Conclusions: Obesity medications introduce unique nutritional risks that are not yet addressed by standardised clinical protocols. Registered dietitians play a critical role in assessing intake patterns, monitoring for red flags, and delivering targeted nutritional support. Integrating structured dietary assessment tools, checklists, and risk-specific guidance into pharmacotherapy pathways can enhance safety, promote adherence, and improve long-term outcomes.
Overview
CoChat Summary
TL;DR
This narrative review argues that GLP-1 receptor agonists and dual GIP/GLP-1 agonists can produce under-recognized nutritional harms—severe caloric restriction, lean mass loss, micronutrient deficiencies, dehydration, and ketosis—that standard pharmacotherapy pathways do not yet address. It proposes dietitian-led monitoring and a practice-oriented checklist, though the checklist has not been validated.
Key findings
- Some patients may consume fewer than 800 kcal/day during early treatment; gastrointestinal adverse events were reported in up to 74% of trial participants, with approximately 7–10% discontinuing due to intolerable symptoms.
- Lean mass loss varies by trial: STEP 1 reported semaglutide-associated lean mass reduction of 6.9 kg (−13.2%) out of 15.3 kg (−14.9%) total weight loss, about 45% of weight lost as lean mass; SURMOUNT-1 attributed 25.7% of weight lost with tirzepatide to lean mass; SUSTAIN-8 reported 2.3 kg (−4.5%) lean mass loss out of 5.3 kg (−6.0%) total weight loss, or 43.4%.
- Micronutrient gaps were common in an exploratory study: average fiber intake was 14.5 g/day versus a recommended 28 g/day, and vitamin D intake was 4 mcg/day; pre-existing deficiency data included 46% vitamin D deficiency in a Chilean severe-obesity cohort and, in a Spanish cohort, 10% vitamin B12, 25% folate, 26% vitamin D, 68% copper, and 74% zinc deficiencies.
- Dehydration and ketosis risks include semaglutide showing the highest risk of fluid reduction-related adverse events in a pharmacovigilance analysis, and liraglutide being associated with increased odds of ketosis in type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8).
Methods
- Narrative review conducted in three stages: literature search, screening of abstracts and full texts, and synthesis of findings.
- Searches were run in April and May 2025 across PubMed, Embase, Scopus, ScienceDirect, Web of Science, and Google Scholar using keywords related to obesity pharmacotherapy and nutrition; only English-language publications were included.
- Eligible sources included clinical trials, observational studies, case reports, practice guidelines, and narrative reviews; no formal PRISMA flow diagram was used.
Limitations
- The authors state that the search was not systematic or meta-analytic, no formal quality appraisal or risk-of-bias tools were applied, and inclusion relied on relevance and clinical judgement, which may introduce subjectivity.
- The authors state that the proposed checklist and targeted strategies were developed from literature and expert practice considerations but have not been validated or empirically tested in clinical settings.
- Evident from the text: some key evidence is indirect or limited, including micronutrient deficiency data drawn from bariatric surgery populations, limited published data on actual caloric intake, and limited evidence on higher GLP-1RA doses used for obesity.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
11 Valid · 3 Not valid · 35 Not checked · 24 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“These findings are consistent with a 2023 meta-analysis showing that liraglutide was associated with a significantly increased odds of ketosis in patients with type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8) [49].”
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > 3. Unintended Health Consequences > 3.5. Ketosis and Ketoacidosis Risk
What the sources say
- Partly supportedcites [44] He, 2024, Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events, Front. Pharmacol. sourceExperimental — accuracy not yet measured
Our copy of He et al. (2024) does state the attributed content in Discussion 4.2 ('A meta-analysis of GLP-1 RAs as adjuvant therapy in patients with T1DM also observed that liraglutide was associated with higher odds of ketosis (OR 1.8; 95% CI, 1.1–2.8)'), matching the population, drug, outcome and effect size. However, the citing sentence attaches this to He et al. as the meta-analysis itself, whereas He et al. only report someone else's result, crediting it to Park et al. (2023) (reference 40: Park J. et al., 'Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis', J. Clin. Endocrinol. Metab. 109, 279–292, 10.1210/clinem/dgad471). The unsupported part is therefore the presentation of this pharmacovigilance study as the source of the 2023 meta-analysis finding; the word 'significantly' is a fair gloss since the reported CI excludes 1. (LLM, conf=0.85)
- Disputedcites [49] Park, 2024, Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: An updated systematic review and meta-analysis, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
Our copy reports a significant increase in ketosis including DKA only for the GLP-1 class overall versus placebo (Table 1 and Adverse Outcomes: M-H OR 1.37, 95% CI 1.04–1.79; Discussion repeats 1.37; 1.04–1.79), and nowhere gives OR 1.8 (95% CI 1.1–2.8) for liraglutide — '1.8' in this paper is a liraglutide dose stratum, not an effect size. More decisively, the Discussion states the opposite of what the claim attributes: 'within each subgroup of GLP-1 analogue regimen (liraglutide 1.8 mg, 1.2 mg, 0.6 mg, exenatide any dose, etc), the odds of hypoglycemia and ketosis were not significantly elevated.' So a liraglutide-specific significant increase in ketosis is contradicted by the source. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several clinical trials of GLP-1 receptor agonists and related pharmacotherapies have reported that a proportion of total weight loss occurs as lean mass, though the magnitude varies by drug, population, and methodology.”
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > 3. Unintended Health Consequences > 3.2. Lean Body Mass Loss and Risk of Sarcopenia
What the sources say
- Partly supportedcites [13] Wilding, 2021, Once-weekly semaglutide in adults with overweight or obesity, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
STEP 1's 'Change in Body Composition' (DXA subpopulation, 140 participants) reports that total lean body mass decreased in absolute terms while the proportion of lean body mass relative to total body mass increased, and the Discussion states that semaglutide 'led to greater reduction in fat mass than lean body mass, a finding consistent with previous findings with semaglutide (at a dose of 1.0 mg) in persons with obesity and in those with type 2 diabetes' — so this source does support that a proportion of semaglutide-associated weight loss occurs as lean mass and that multiple trials report it. However, the source does not support the claim's second half: it says nothing about the magnitude of lean-mass loss varying by drug, population, or methodology. Its only cross-study caveat concerns total weight reduction versus liraglutide ('these two studies differed in their participant population, which limits the robustness of between-study comparisons'), not body composition, and its body-composition data come from a single small DXA substudy rather than a survey of GLP-1 trials or 'related pharmacotherapies'. (LLM, conf=0.72)
- Not checked yetcites [15] Jastreboff, 2022, Tirzepatide once weekly for the treatment of obesity, N. Engl. J. Med. source
- Supportedcites [30] McCrimmon, 2020, Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial, Diabetologia source
The Discussion (p. n/a) states 'Similar results were observed in trials assessing body composition with other GLP-1RAs', citing the LEAD-2 substudy (liraglutide: fat mass -2.4 kg, lean mass -1.5 kg) alongside case-series in which skeletal muscle mass was unchanged, and explicitly cautions that 'indirect comparisons across clinical trials should be interpreted with caution, given the heterogeneity of the study populations'. The same section reports variation across related pharmacotherapy (SGLT-2i) trials — ipragliflozin with near-equal fat (1.8 kg) and lean (1.7 kg) losses versus DXA-based canagliflozin/dapagliflozin trials showing fat 2.2-2.4 kg vs lean 1.1-1.2 kg — and the Discussion/Strengths-and-weaknesses sections attribute methodological divergence to DXA's inability to separate muscle from non-muscle lean components and fluid. The Results ('Change in total lean mass') corroborate a lean-mass component of weight loss in this substudy (-2.3 kg semaglutide, -1.5 kg canagliflozin). (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Reduction in appetite can be significant, particularly during the initial titration phase of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual GIP/GLP-1 receptor agonists [21,22].”
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > 3. Unintended Health Consequences > 3.1. Severe Energy Deficit and Inadequate Caloric Intake
What the sources say
- Partly supportedcites [21] Moiz, 2025, Mechanisms of GLP-1 receptor agonist-induced weight loss: A review of central and peripheral pathways in appetite and energy regulation, Am. J. Med. sourceExperimental — accuracy not yet measured
Our copy supports the substantive core: the INTRODUCTION states 'GLP-1 RAs suppress appetite and enhance satiety by acting on the central nervous system which leads to reduced caloric consumption and weight loss,' the CLINICAL SIGNIFICANCE section repeats appetite suppression/satiety enhancement, and the 'Glucose-Dependant Insulinotropic Polypeptide RAs' and 'DUAL/TRIPLE CO-AGONIST-INDUCED WEIGHT LOSS' sections cover dual GIP/GLP-1 co-agonists (tirzepatide) acting on appetite regulation. However, the temporal qualifier the claim carries — that the appetite reduction is 'particularly' pronounced during the initial titration phase — is not stated anywhere in our copy: four searches (titration/dose escalation, early-week timing, greatest-at-start-and-attenuating, and the claim's distinctive phrases) returned no passage addressing dose titration or the time course of appetite suppression; this review discusses mechanisms, not treatment-phase dynamics. (LLM, conf=0.72)
- Not checked yetcites [22] Bettge, 2017, Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials, Diabetes Obes. Metab. source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In the STEP-HFpEF trial, semaglutide treatment in patients with obesity-related HFpEF led to significant improvements in the 6-min walk distance (6MWD) and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), despite concurrent losses in lean mass [38].”
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > 3. Unintended Health Consequences > 3.2. Lean Body Mass Loss and Risk of Sarcopenia
What the sources say
- Partly supportedcites [38] Kosiborod, 2023, Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings are consistent with a 2023 meta-analysis showing that liraglutide was associated with a significantly increased odds of ketosis in patients with type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8) [49].”
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > 3. Unintended Health Consequences > 3.5. Ketosis and Ketoacidosis Risk
What the sources say
- Partly supportedcites [49] Park, 2024, Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: An updated systematic review and meta-analysis, J. Clin. Endocrinol. Metab. sourceExperimental — accuracy not yet measured
The Adverse Outcomes section reports significantly increased odds of ketosis, including DKA, for GLP-1 agonists overall in patients with type 1 diabetes. But it gives an OR of 1.34 (95% CI, 1.04–1.79), not 1.8 (1.1–2.8); the Discussion gives 1.37 (1.04–1.79) and says it is unclear whether a particular GLP-1 analogue has a higher ketosis risk. The cited result therefore does not establish the stated estimate specifically for liraglutide. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
29 more claims · 1 with their cited sources checked
Create a free account to see all 73 claims and to verify the 43 references still open.
- It may state two separate claims as one. 29
- Probably not a substantial claim. 12
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Symptoms such as reduced appetite, early satiety, and nausea may limit dietary variety and protein intake, leading to muscle loss [63,64,65].”
From Nutrition and Physical Activity in Optimizing Weight Loss and Lean Mass Preservation in the Incretin-Based Medications Era: A Narrative Review (2025) · cites this paper as [65]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > 3. Unintended Health Consequences > 3.5. Ketosis and Ketoacidosis Risk
“These findings are consistent with a 2023 meta-analysis showing that liraglutide was associated with a significantly increased odds of ketosis in patients with type 1 diabetes (OR 1.8; 95% CI, 1.1–2.8) [49].”
§ Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes > References
“49. Park J. Ntelis S. Yunasan E. Downton K.D. Yip T.C.-F. Munir K.M. Haq N. Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: An updated systematic review and meta-analysis J. Clin. Endocrinol. Metab. 2024 109 279 292”
Citations
Cites
Sarcopenia: revised European consensus on definition and diagnosis
Cruz-Jentoft, A. J., Bahat, G., Bauer, J., Boirie, Y., Bruyère, O., Cederholm, T., Cooper, C., Landi, F., Rolland, Y., Sayer, A. A., et al. (2019) · Age and Ageing · doi:10.1093/ageing/afy169 · Cited by 13,818 · cited 1×
“This is of particular concern in older adults, where muscle loss contributes to frailty, impaired glucose regulation, increased fall risk, and decreased quality of life [33].”
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 2×
“%) weight loss, representing approximately 45% of the total weight lost as lean mass [13].”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“In the SURMOUNT-1 trial of tirzepatide, 25.7% of weight lost was attributed to lean mass [15].”
InfluentialBody Fatness and Cancer — Viewpoint of the IARC Working Group
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Grosse, Y., Bianchini, F., & Straif, K. (2016) · New England Journal of Medicine · doi:10.1056/nejmsr1606602 · Cited by 3,596 · cited 1×
“Excess adiposity is a major risk factor for a wide range of chronic conditions, including cardiovascular diseases [2,3], type 2 diabetes [2], chronic kidney disease [2], several types of cancer [4], and musculoskeletal disorders [5,6].”
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 1×
“Semaglutide 2.4 mg, for example, has been associated with mean weight loss exceeding 15% of initial body weight over 68 weeks [13], while liraglutide 3.0 mg typically results in 5–7% weight loss [14].”
InfluentialDeutz, N. E. P., Bauer, J. M., Barazzoni, R., Biolo, G., Boirie, Y., Bosy-Westphal, A., Cederholm, T., Cruz-Jentoft, A., Krznariç, Z., Nair, K. S., et al. (2014) · Clinical Nutrition · doi:10.1016/j.clnu.2014.04.007 · Cited by 1,738 · cited 1×
“While the primary goal of obesity treatment is to reduce excess adiposity, unintended loss of muscle mass can impair resting metabolic rate, compromise physical function, and increase the risk of sarcopenia, especially in older adults or individuals with lower baseline muscle reserves [27,28].”
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 2×
“…muscle function may be preserved or even improved, despite decreases in muscle mass. Nonetheless, proactive strategies to maintain or enhance muscle mass, such as resistance training and adequate protein intake, may further amplify the functional benefits conferred by these pharmacotherapies [38].”
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444 · cited 1×
“Common adverse effects include nausea, vomiting, diarrhea, constipation, early satiety, dyspepsia, hypodipsia, and anorexia [17,18].”
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 1×
“Common adverse effects include nausea, vomiting, diarrhea, constipation, early satiety, dyspepsia, hypodipsia, and anorexia [17,18].”
Cited by
Sibal, R., Balamurugan, G., Langley, J., Graham, Y., & Mahawar, K. K. (2025) · Nutrients · doi:10.3390/nu17233659 · Cited by 30
“A recent systematic review described cases of severe caloric restriction ( 800 kcal/day), frequently accompanied by suboptimal intake of macro-and micronutrients, representing a clinically significant risk [22].”
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
“When appropri - ately tailored to the individual, these diets may complement semaglutide therapy by supporting treatment adherence, enhancing metabolic outcomes, and potentially mitigating GI AEs.”
Barana, L., De Fano, M., Cavallo, M., Manco, M., Prete, D., Fanelli, C. G., Porcellati, F., & Pippi, R. (2025) · Nutrients · doi:10.3390/nu18010131 · Cited by 13
“Symptoms such as reduced appetite, early satiety, and nausea may limit dietary variety and protein intake, leading to muscle loss [63–65].”
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Zambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 8
“Most individuals presenting for obesity pharmacotherapy demonstrate dietary patterns characterized by high energy density and low overall diet quality, often with irregular meal timing and reliance on ultra-processed foods [83].”
Metadata
- Authors
- Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W.
- Affiliations
- Diabetes Complications Research Centre, School of Medicine, Conway Institute, University College Dublin, D04 V1W8 Dublin, Ireland
- Universidade Lusófona de Humanidades e Tecnologias (PT)
- Shaqra University (SA)
- Corresponding author
- Raposo, António
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2025-06-05
- Volume
- 17
- Issue
- 11
- Pages
- 1934
- ISSN
- 2072-6643 (ISSN-L)
- PMC
- PMC12157928
- OpenAlex
- W4411070513
- Cited by
- 16
- References
- 50
- Citations by year
- 2026: 12 · 2025: 4
- FWCI
- 2.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nutrients (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Nursing › Nutrition and Dietetics › Dietetics, Nutrition, and Education
- Keywords
- obesity pharmacotherapy, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, nutritional complications, caloric restriction, micronutrient deficiency, sarcopenia, lean mass loss, dehydration, ketoacidosis, medication adherence, registered dietitians, dietary assessment, older adults
- MeSH terms
- Humans, Nutritional Status, Obesity, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. https://app.cochat.ai/papers/10.3390/nu17111934
- The paper
- Al-Najim, W., Raposo, A., BinMowyna, M. N., & le Roux, C. W. (2025). Unintended Consequences of Obesity Pharmacotherapy: A Nutritional Approach to Ensuring Better Patient Outcomes. Nutrients. https://doi.org/10.3390/nu17111934
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

